Trial NCT04374253

View at ClinicalTrials.gov 
Org. Study IDs: WN42171
Secondary IDs: 2020-000766-42

Last trial update was posted on 2023-03-28

MeSH Interventions

Antibodies, Monoclonal

MeSH Conditions

Alzheimer Disease

Other Conditions


Stopping Reasons

Decision to terminate development of Gantenerumab for treatment of prodromal/mild/early-stage Alzheimer's disease following results of a pre-planned analysis of the safety and efficacy of Gant in Graduate I&II (WN29922/WN39658).

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID